research use only
Cat.No.S3894
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase |
|---|---|
| Other Telomerase Inhibitors | EGCG ((-)-Epigallocatechin Gallate) BIBR 1532 Costunolide RHPS 4 methosulfate Cyclogalegenol Epitalon MST-312 L-778123 hydrochloride TAC (TERT Activator-1) Braco-19 trihydrochloride |
| Molecular Weight | 490.72 | Formula | C30H50O5 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 84605-18-5 | -- | Storage of Stock Solutions |
|
|
| Synonyms | CAG, TA-65, Cyclogalegigenin, Astramembrangenin | Smiles | CC1(C(CCC23C1C(CC4C2(C3)CCC5(C4(CC(C5C6(CCC(O6)C(C)(C)O)C)O)C)C)O)O)C | ||
|
In vitro |
DMSO
: 98 mg/mL
(199.7 mM)
Ethanol : 25 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
telomerase
|
|---|---|
| In vitro |
Cycloastragenol stimulates telomerase activity and cell proliferation in human neonatal keratinocytes. It induces telomerase activity and cAMP response element binding (CREB) activation in PC12 cells and primary neurons. This compound treatment not only induces the expression of bcl2, a CREB-regulated gene, but also the expression of telomerase reverse transcriptase in primary cortical neurons. It rapidly passes through the Caco-2 cell monolayer by passive diffusion. Once passage through the intestinal epithelium, first-pass intestinal metabolism of this chemical might occur. It can undergo extensive metabolism in rat and human liver microsomes.
|
| In vivo |
Oral administration of cycloastragenol (CA) for 7 days attenuates depression-like behaviour in experimental mice. Oral bioavailability of this compound is about 25.70% at 10 mg/kg. It is excreted through bile and faeces and eliminated predominantly by the kidney in rats. There might also exist an enterohepatic circulation of this chemical in rats. It could be metabolised widely in vivo in rats. For oral administration the mean Tmax at 10 mg/kg, 20 mg/kg, and 40 mg/kg is 2.06±0.58 h, 1.48±0.36 h, and 2.35± 1.17 h. The t1/2 is 5.23±1.55 h, 7.33±3.03 h, and 6.06± 3.42 h, respectively. The mean absorption time of this compound at 10 mg/kg is 5.70± 1.62 h; the poor absorption could be caused by the low solubility. The pharmacokinetic parameters show no significant differences among the groups of 10, 20, and 40 mg/kg except for Cmax and AUC.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05777083 | Recruiting | ST Elevation Myocardial Infarction|Electrocardiogram |
Ewha Womans University Mokdong Hospital |
January 1 2023 | Not Applicable |
| NCT05578443 | Recruiting | Alzheimer''s Disease |
Fujian Medical University Union Hospital |
October 1 2022 | Phase 2 |
| NCT05528744 | Recruiting | Genetic Disease|Chopra-Amiel-Gordon Syndrome|CAGS|ANKRD17 |
Boston Children''s Hospital |
August 27 2022 | -- |
| NCT05533528 | Recruiting | Periodontal Pocket|Periodontal Diseases|Periodontal Bone Loss |
Universidad de Murcia |
May 3 2022 | Not Applicable |
| NCT05118009 | Completed | Myocardial Infarction Acute |
National Defense Medical Center Taiwan |
May 1 2022 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.